Lexicon Pharmaceuticals (LXRX) Rating Increased to Sell at BidaskClub

Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts also recently weighed in on LXRX. ValuEngine downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $28.50.

Shares of Lexicon Pharmaceuticals (LXRX) opened at $10.44 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals has a twelve month low of $8.07 and a twelve month high of $18.00. The firm has a market capitalization of $1,120.00, a price-to-earnings ratio of -8.22 and a beta of 0.10.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same quarter last year, the business posted ($0.35) EPS. Lexicon Pharmaceuticals’s revenue for the quarter was down 2.8% on a year-over-year basis. research analysts forecast that Lexicon Pharmaceuticals will post -1.38 earnings per share for the current year.

In other Lexicon Pharmaceuticals news, CEO Lonnel Coats acquired 10,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average cost of $9.91 per share, with a total value of $99,100.00. Following the transaction, the chief executive officer now owns 42,985 shares in the company, valued at approximately $425,981.35. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Public Equities L.P. Invus acquired 575,946 shares of the stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $9.64 per share, with a total value of $5,552,119.44. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 914,353 shares of company stock valued at $8,916,253. 5.77% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 17.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 134,043 shares of the biopharmaceutical company’s stock worth $2,205,000 after acquiring an additional 20,379 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth about $9,420,000. Ameriprise Financial Inc. bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $1,261,000. Malaga Cove Capital LLC bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth about $521,000. Finally, Pinnacle Associates Ltd. raised its position in shares of Lexicon Pharmaceuticals by 25.5% in the 3rd quarter. Pinnacle Associates Ltd. now owns 897,045 shares of the biopharmaceutical company’s stock worth $11,025,000 after acquiring an additional 182,215 shares in the last quarter.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/20/lexicon-pharmaceuticals-lxrx-rating-increased-to-sell-at-bidaskclub.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply